XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Bladder Carcinoma. According to GlobalData, Phase I drugs for Bladder Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the XBH-25 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XBH-25 overview

XHB-25 is under development for the treatment of advanced or refractory solid tumor malignancies, bladder urothelial carcinoma, bile duct cancer (cholangiocarcinoma), adenocarcinoma of the colon or rectum, endometrial carcinoma,  head and neck squamous cell carcinoma, cutaneous melanoma, non-small cell lung cancer. It is administered through intravenous route and is being developed based on GV20 genomics and GV20 artificial intelligence (AI) platform. It acts by targeting IGSF8 (Immunoglobulin Superfamily Member 8). 

GV20 Therapeutics overview

GV20 Therapeutics develops novel cancer immunology drugs and antibody therapeutics utilizing functional genomics and artificial intelligence platform to exploit vulnerabilities in cancer biology. GV20 Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of XBH-25’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.